Studies have revealed a greater level of PD-L1 protein expression in KRAS- or TP53-mutant NSCLC than in nonmutant tumors, suggesting that KRAS may participate in immune system inhibition via PD-L1 145. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.